MCK Stock Analysis 2025: Why McKesson Could See Short-Term Growth

McKesson Corporation (NYSE: MCK) is one of the largest American healthcare distributors, providing pharmaceuticals, specialty drugs, and medical supplies to hospitals and pharmacies across the United States. With rising demand for specialty drugs and an expanding healthcare market, McKesson is positioned for growth.

Technical Analysis: EMA and RSI

• EMA (Exponential Moving Average): The 50-day EMA has recently crossed above the 200-day EMA, forming a bullish golden cross, signaling potential upward momentum in the stock price.

• RSI (Relative Strength Index): The RSI is around 62, indicating bullish momentum without being overbought. An RSI between 50–70 generally signals room for continued growth.

• Support & Resistance Levels: Strong support is near $860–$870, and resistance lies around $900–$915. A breakout above $915 could trigger further gains.

Why MCK Could Grow

1. U.S. Healthcare Tailwinds: Specialty drugs and medical supply demand continues to rise, supporting revenue growth.

2. Raised Guidance: McKesson recently upgraded its fiscal 2026 profit forecast, showing confidence in its outlook.

3. Analyst Optimism: Several U.S. investment firms raised price targets, citing both strong fundamentals and technical momentum.

4. Technical Momentum: EMA golden cross and RSI in bullish range indicate potential short-term upside.

Risks to Watch

• U.S. healthcare policy changes (drug pricing, regulations) could impact margins.

• Technical pullbacks may occur if RSI approaches overbought levels above 70.

• Broader market volatility may temporarily affect the stock despite strong sector fundamentals.

Short-Term Outlook

Based on technical indicators and fundamental tailwinds, MCK shows strong potential for near-term growth. Traders could consider buying near $860–$870 support, aiming for potential upside toward $900–$915 in the coming weeks.

Summary

McKesson offers a combination of solid U.S. healthcare fundamentals and favorable technical signals. The EMA golden cross and bullish RSI suggest the stock could experience near-term gains, making it attractive for U.S. investors and short-term traders looking for exposure to the healthcare sector.

Investment View: Moderate Buy - strong technical and fundamental setup for short-term upside.

Disclaimer:
This article is for informational purposes only and is not financial advice. Always conduct your own research or consult a licensed financial advisor before investing.